PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

Novartis’ Cosentyx gets CHMP positive opinion for use in childhood arthritic conditions

05/23/2022 by PharmaLeaders Aggregator

The positive opinion for use of Cosentyx either alone or in combination with methotrexate has been given for the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) The post Novartis’ Cosentyx gets CHMP positive opinion for use in childhood arthritic conditions appeared first on Pharmaceutical Business review. … [Read more...]

FDA Places Partial Clinical Hold on Foghorn’s AML and MDS Study Due to Patient Death

05/23/2022 by PharmaLeaders Aggregator

Patients currently enrolled in the study can continue to receive treatment, but no new patients can be enrolled. … [Read more...]

Drug Delivery West (5/23/22 – 5/24)

05/23/2022 by PharmaLeaders Aggregator

… [Read more...]

Artax Biopharma to develop oral small molecule immunomodulating agent

05/21/2022 by PharmaLeaders Aggregator

The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with The post Artax Biopharma to develop oral small molecule immunomodulating agent appeared first on Pharmaceutical Business review. … [Read more...]

Moma Therapeutics completes funding for precision oncology programmes

05/20/2022 by PharmaLeaders Aggregator

The financing round saw participation from other new investors Pavilion Capital, Section 32, Invus and LifeSci Venture Partners. All of the Series A investors of Moma including Third The post Moma Therapeutics completes funding for precision oncology programmes appeared first on Pharmaceutical Business review. … [Read more...]

Next Page »
  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2022 PharmaLeaders.com. All rights reserved.

Copyright © 2022 · Magazine Pro Theme on Genesis Framework · WordPress · Log in